📄 medicine

Neurological Manifestations of Inborn Errors of Metabolism Among Patients With Confrimed Genetic Mutation in a Kenyan Tertiary Referral Centre

This retrospective study of 92 patients at a Kenyan tertiary referral centre found that inborn errors of metabolism accounted for over half of genetically confirmed diagnoses among those with CNS manifestations, with hemizygous variant status and targeted metabolic gene panels identified as the strongest independent predictors of an IEM diagnosis.

Original authors: Mungai Wainaina L. N., Miller Danny, Kaumbulu M Cleopas, Michuki Maina, Were Fred N, Amaratunga Shenali Anne, Wamalwa Dalton N.

Published 2026-08-06

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Mungai Wainaina L. N., Miller Danny, Kaumbulu M Cleopas, Michuki Maina, Were Fred N, Amaratunga Shenali Anne, Wamalwa Dalton N.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your body is a bustling, high-tech city. Every street, building, and power plant relies on a complex network of delivery trucks bringing in fuel and taking out trash. Most of the time, this system runs smoothly. But sometimes, a specific truck breaks down or a delivery route gets blocked. In the world of medicine, these breakdowns are called "Inborn Errors of Metabolism" (IEM). They are like tiny, hidden glitches in the body's instruction manual that stop it from processing food and energy correctly.

The most vulnerable part of this city is the brain. Think of the brain as the city's central command center. It burns fuel faster than any other building and has very little backup power. If the delivery trucks stop or the trash piles up, the command center is the first to go dark. This leads to problems like developmental delays, seizures, or learning difficulties. The tricky part is that these metabolic glitches often look exactly like other common childhood issues, making them hard to spot. It's like trying to find a specific broken wire in a tangled mess of Christmas lights; you might see the whole string is dark, but figuring out which wire is broken takes a special kind of detective work.

The Detective Story in Kenya

This study is like a detective report from a major hospital in Kenya, where researchers decided to play detective with 92 young patients (aged 25 and under) who were already showing signs of trouble in their "central command centers." These kids had genetic testing done because doctors suspected their bodies might be struggling with these metabolic glitches. The researchers wanted to see: out of all these kids with confirmed genetic mutations, how many actually had a metabolic error (IEM), and what clues could help doctors spot them faster?

The Big Reveal
The results were quite clear. Out of the 92 kids with confirmed genetic mutations, 51 of them (55.4%) were found to have Inborn Errors of Metabolism. The other 41 kids had different inherited conditions that weren't metabolic in nature. This means that within this specific group of patients referred to the hospital, metabolic errors accounted for more than half of the genetically confirmed diagnoses.

The Clues: What to Look For
The researchers played a game of "spot the difference" between the kids with metabolic errors and those without. They found some very strong clues that pointed toward a metabolic diagnosis:

The "Boy" Clue: The study found a strong link between being male and having a metabolic error. About 72% of the patients in the study were boys. The researchers suggest this is because many of the metabolic errors found here are "X-linked," meaning the broken instruction manual is on a chromosome that boys only have one of (making them more likely to show the symptoms).
The "Family Tree" Clue: If a child had a family history of similar illnesses or siblings who were also affected, they were more likely to have a metabolic error.
The "Face" Clue: Children with unusual physical features (dysmorphic features) were more likely to have a metabolic error.
The "Test" Clue: This was a big one. Kids who were tested with a Targeted Metabolic Gene Panel (a test that looks specifically at known metabolic genes) were much more likely to have a metabolic error than those tested with a "Whole-Exome Sequencing" test (which looks at all genes). It's like using a metal detector to find a specific type of coin versus digging up the whole beach to see what's there.

What the Study Said "No" To
The study also ruled out some things that people might expect to be clues.

Autism: Surprisingly, kids with autistic features were less likely to have a metabolic error in this group. About 61% of the non-metabolic kids had autistic features, compared to only 25.5% of the metabolic kids. This suggests that if a child's main issue is behavioral or autistic without other major physical signs, it might be a primary developmental issue rather than a metabolic one.
Epilepsy and Speech Delays: Similarly, seizures (epilepsy) and speech delays were actually less common in the group with metabolic errors. In this study, these symptoms were significantly less likely to appear in the metabolic group (15.7% for epilepsy and 41.2% for speech delays) compared to the non-metabolic group (46.3% for epilepsy and 75.6% for speech delays). While metabolic errors can cause seizures, in this specific group of Kenyan patients, those symptoms pointed more strongly toward other types of genetic conditions.

The "Time Travel" Problem
One of the saddest findings was about time. The kids with metabolic errors waited much longer to get their diagnosis. On average, they were diagnosed at 7.7 years old, while the other group was diagnosed at 5.2 years old. The researchers note that this delay is a global problem. Because these conditions are rare and hard to spot, kids often spend years getting treatment for the wrong things before the real cause is found. The study suggests that using the right "clues" (like family history and targeted tests) could help doctors solve the mystery much faster, potentially saving the brain from long-term damage.

The Bottom Line
This paper doesn't claim to have solved all the mysteries of metabolism, but it gives doctors in Kenya (and similar places) a better map. It tells them: "If you see a boy with developmental delays, a family history of similar issues, and maybe some unusual facial features, and you suspect a metabolic error, use a targeted test for metabolic genes." By following these clues, doctors might be able to catch these hidden glitches before they cause too much damage to the city's command center.

Technical Summary: Neurological Manifestations of Inborn Errors of Metabolism in a Kenyan Tertiary Referral Centre

Problem Statement
Inborn errors of metabolism (IEMs) are rare, inherited conditions characterized by biochemical derangements that disproportionately affect the central nervous system (CNS) due to its high energy requirements and limited regenerative capacity. While neurological features such as developmental delay, intellectual disability, and epilepsy are often the earliest and most disabling manifestations, the clinical heterogeneity of IEMs and their overlap with common neurodevelopmental disorders frequently lead to diagnostic uncertainty and significant delays. In low- and middle-income countries (LMICs) like Kenya, the lack of population-based screening and restricted access to specialized genomic services exacerbates these delays, resulting in recurrent hospitalizations, avoidable neurological injury, and premature mortality. There is a substantive gap in literature regarding the specific phenotypic and molecular spectrum of IEMs presenting with CNS manifestations in sub-Saharan Africa, where data is largely dominated by high-income healthcare systems.

Methodology
This study employed a retrospective cross-sectional design conducted at a Kenyan tertiary referral centre (Kenyatta National Hospital) between January 2018 and February 2026. The study population consisted of 92 patients aged 25 years or younger, along with their biological relatives, who presented with CNS manifestations and underwent genetic evaluation for suspected IEM.

Inclusion Criteria: Individuals with confirmed pathogenic or likely pathogenic variants on molecular analysis.
Data Collection: Clinical, demographic, and genomic data were extracted from medical records. This included family history, physical examination findings (e.g., dysmorphic features), and molecular data (gene mutations, zygosity, mutation type).
Statistical Analysis: Descriptive statistics were used for summarization. Associations between clinical features and IEM diagnosis were assessed using Pearson's chi-squared test or Fisher's exact test. Unadjusted odds ratios (OR) were calculated for bivariate analysis, and variables with $p < 0.20$ were entered into a multivariable binary logistic regression model to identify independent predictors (adjusted OR). Statistical significance was defined as $p < 0.05$ .

Key Results
The study cohort comprised 92 patients with confirmed genetic variants and CNS manifestations. Of these, 51 patients (55.4%) received a diagnosis of IEM, while 41 (44.6%) were assigned non-IEM inherited conditions.

Demographics and Onset: The cohort showed a male predominance (71.7%). The median age at symptom onset was 1.0 year, with the majority of cases manifesting between 12 and 24 months. The median age at confirmed diagnosis was significantly higher in the IEM group (7.7 years) compared to the non-IEM group (5.2 years).
Clinical Phenotypes:
- IEM Group: The most prevalent features were motor delay (51.0%), intellectual impairment (47.1%), and cognitive impairment (45.1%). Dysmorphic features were present in 54.9% of IEM patients.
- Non-IEM Group: Autistic features were substantially more prevalent in this group (61.0% vs. 25.5% in IEM). Epilepsy (46.3% vs. 15.7%), hyperkinesia (34.1% vs. 11.8%), and speech/language delay (75.6% vs. 41.2%) were also more common in non-IEM patients.
Genetic Characteristics:
- Zygosity: Hemizygous variants were significantly more common in the IEM group (52.9%) compared to the non-IEM group (9.8%).
- Testing Modality: Targeted metabolic gene panels were used more frequently for IEM diagnoses (43.1%) compared to whole-exome sequencing (WES), which was predominantly used for non-IEM cases (87.8%).
- Genotype-Phenotype Correlations: Within the IEM group, IDS (Iduronate-2-sulfatase) variants were recurrently associated with all CNS phenotypic domains, consistent with Hunter syndrome (MPS II). PAH (Phenylalanine hydroxylase) variants were linked to broad neurocognitive involvement. Epilepsy in the IEM group was primarily associated with mitochondrial complex I deficiency (NDUFS4) and urea cycle dysfunction (OTC).

Predictors of Diagnosis

Bivariate Analysis: Positive family history of similar illness, dysmorphic features, hemizygous variant status, and X-linked inheritance were all significantly associated with an IEM diagnosis. Conversely, autistic features, epilepsy, hyperkinesia, and speech/language delay were negatively associated with IEM.
Multivariable Analysis: After adjustment, two factors emerged as the strongest independent predictors of an IEM diagnosis:
1. Hemizygous variant status: Adjusted OR (aOR) 31.2 (95% CI 5.97–250; $p < 0.001$ ).
2. Use of a targeted metabolic gene panel: aOR 9.32 (95% CI 1.58–73.5; $p = 0.020$ ).
  Other factors, including family history and dysmorphic features, lost statistical significance in the multivariable model.

Significance and Claims
The authors claim that this study provides one of the first systematic characterizations of IEM genetics presenting with CNS manifestations in sub-Saharan Africa. Key contributions and claims include:

Prevalence: IEMs account for more than half (55.4%) of genetically confirmed diagnoses among patients presenting with CNS manifestations at this Kenyan tertiary centre.
Diagnostic Guidance: The study identifies that structured clinical assessment combined with specific molecular testing strategies can improve diagnostic accuracy. Specifically, the presence of hemizygous variants and the use of targeted metabolic gene panels are strong indicators for IEM.
Clinical Differentiation: The findings suggest that while global impairment (motor delay, intellectual/cognitive deficits) is characteristic of IEM, isolated behavioral phenotypes (autism) and specific neurological signs (epilepsy, hyperkinesia) in this cohort were more indicative of primary neurodevelopmental conditions.
Regional Context: The high male predominance in this cohort is attributed to the prevalence of X-linked disorders (specifically MPS II and G6PD deficiency), contrasting with Egyptian cohorts where autosomal recessive conditions predominated. This highlights the influence of population genetics and testing methodologies (targeted panels vs. biochemical screening) on diagnostic yields.
Call to Action: The authors emphasize that diagnostic delays remain a critical issue, with a median delay of 7.7 years for IEM cases. They argue that early integration of genomic and metabolic evaluation, potentially through targeted panels for treatable conditions, is essential to shorten diagnostic delays and facilitate timely therapeutic interventions in resource-limited settings.

The study acknowledges limitations, including its retrospective single-centre design which may introduce survivorship bias (underrepresenting severe neonatal phenotypes that result in early mortality) and a relatively small sample size. However, it asserts that the molecular confirmation of all diagnoses provides a robust basis for genotype-phenotype analysis in an underrepresented region.

Technical Summary: Neurological Manifestations of Inborn Errors of Metabolism in a Kenyan Tertiary Referral Centre

More like this